<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Property</title>
	<atom:link href="http://www.tapanray.in/tag/property/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Exploiting India&#8217;s Weakness For Monopolistic Commercial Gain?</title>
		<link>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exploiting-indias-weakness-for-monopolistic-commercial-gain</link>
		<comments>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/#comments</comments>
		<pubDate>Mon, 08 May 2023 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10776</guid>
		<description><![CDATA[Public access to healthcare in India is a complex issue with several challenges. While India has been making progress over the years in improving healthcare access and reducing the burden of disease, there are still significant disparities in healthcare access &#8230; <a href="http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exploiting-indias-weakness-for-monopolistic-commercial-gain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer Care: Dawns A New Era Of Precision Medicine In India</title>
		<link>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cancer-care-dawns-a-new-era-of-precision-medicine-in-india</link>
		<comments>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/#comments</comments>
		<pubDate>Mon, 22 Aug 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[dawn]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[one-size-fits-all]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmacogenomics]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7779</guid>
		<description><![CDATA[The concept of ‘Precision Medicine’ has started gaining increasing importance, in the treatment process of many serious diseases, such as cancer. It is now happening in many countries of the world, including India. The National Institutes of Health (NIH) of &#8230; <a href="http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Utility Model: Would It Work In India For Pharma?</title>
		<link>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=utility-model-would-it-work-in-india-for-pharma</link>
		<comments>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/#comments</comments>
		<pubDate>Mon, 08 Jun 2015 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[dimethyl]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Forward Pharma A/S]]></category>
		<category><![CDATA[fumarate]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tecfidera]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Utility]]></category>
		<category><![CDATA[Utility Model]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6704</guid>
		<description><![CDATA[The revised draft of India&#8217;s IPR Policy penned by the Government constituted ‘Think-Tank’ in 2014, suggests enactment of new laws, such as for ‘Utility Models’ and Trade Secrets, to fill some gaps in the country&#8217;s IPR ecosystem . However, media reports &#8230; <a href="http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TPP: Discord Within A Strange Mélange And Impact On Access To Medicines</title>
		<link>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines</link>
		<comments>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/#comments</comments>
		<pubDate>Mon, 25 May 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[access to medicines]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[democrats]]></category>
		<category><![CDATA[discord]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[geopolitical]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mélange]]></category>
		<category><![CDATA[Pacific]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Trans]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WikiLeaks]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6665</guid>
		<description><![CDATA[On May 19, 2015, Bloomberg reported that a sizable number of President Barack Obama’s own party colleagues, besides teachers, seniors, Internet freedom groups and nuns, have joined the push to defeat the proposed Trans-Pacific Partnership (TPP) treaty. Before I delve into the TPP, &#8230; <a href="http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tpp-discord-within-a-strange-melange-and-impact-on-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reverberations Around The Proposed New IPR Policy Of India</title>
		<link>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reverberations-around-the-proposed-new-ipr-policy-of-india</link>
		<comments>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/#comments</comments>
		<pubDate>Mon, 16 Feb 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Arjun Jayadev]]></category>
		<category><![CDATA[Barack]]></category>
		<category><![CDATA[Dean Baker]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[World Trade Organization (WTO)]]></category>
		<category><![CDATA[‘Project Syndicate’]]></category>
		<category><![CDATA[‘The World Opinion Page’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6381</guid>
		<description><![CDATA[“If the Obama administration succeeds in forcing India to strengthen its patent laws, the change would harm not only India and other developing countries; it would also enshrine a grossly corrupt and inefficient patent system in the US, in which &#8230; <a href="http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reverberations-around-the-proposed-new-ipr-policy-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?</title>
		<link>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients</link>
		<comments>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/#comments</comments>
		<pubDate>Mon, 06 Oct 2014 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[Baker]]></category>
		<category><![CDATA[Brook]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[conceded]]></category>
		<category><![CDATA[Forum]]></category>
		<category><![CDATA[ground. America]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jamie]]></category>
		<category><![CDATA[Kher]]></category>
		<category><![CDATA[Love]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Northeastern]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Rajeev]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6060</guid>
		<description><![CDATA[Unprecedented high profile engagement of the Indian Prime Minister with various interested groups during his recent visit to the United States under equally unprecedented media glare, has invited overwhelmingly more kudos than brickbats, from across the world. However, in the &#8230; <a href="http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New &#8216;Modi Government&#8217;: Would Restoring Cordial Relationship with America Be As Vital As Calling Its Bluff On IP?</title>
		<link>http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip</link>
		<comments>http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/#comments</comments>
		<pubDate>Mon, 26 May 2014 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[bluff]]></category>
		<category><![CDATA[calling]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5424</guid>
		<description><![CDATA[Newspaper reports are now abuzz with various industry groups’ hustle to lobby before the ‘Modi Government’ on their expectations from the new regime. This includes the pharmaceutical industry too. The reports mention that the industry groups, including some individual companies, have &#8230; <a href="http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“India is The Biggest Battlefield for Intellectual Property Rights”</title>
		<link>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-is-the-biggest-battlefield-for-intellectual-property-rights</link>
		<comments>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/#comments</comments>
		<pubDate>Wed, 05 Feb 2014 05:59:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[battlefield]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Biggest]]></category>
		<category><![CDATA[body]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Consilium]]></category>
		<category><![CDATA[dispute]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Israel]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[PAE]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Pugatch]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[restoration]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[settlement]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[term]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4965</guid>
		<description><![CDATA[The US Senator Orrin Hatch reportedly made the above comment while introducing the 2014 report on ‘International Intellectual Property (IP) Index’, prepared by an Israel based consultancy firm &#8211; Pugatch Consilium for the Global Intellectual Property Centre (GIPC) of the &#8230; <a href="http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
